share_log

Zhejiang Hisun BiomaterialsLtd's (SHSE:688203) Weak Earnings May Only Reveal A Part Of The Whole Picture

Zhejiang Hisun BiomaterialsLtd's (SHSE:688203) Weak Earnings May Only Reveal A Part Of The Whole Picture

浙江海正生物材料有限公司(上海證券交易所代碼:688203)的疲軟收益可能只能揭示整體情況的一部分
Simply Wall St ·  04/01 18:07

The subdued market reaction suggests that Zhejiang Hisun Biomaterials Co.Ltd.'s (SHSE:688203) recent earnings didn't contain any surprises. However, we believe that investors should be aware of some underlying factors which may be of concern.

疲軟的市場反應表明,浙江海正生物材料有限公司”s(上海證券交易所代碼:688203)最近的收益沒有任何意外。但是,我們認爲,投資者應注意一些可能令人擔憂的潛在因素。

earnings-and-revenue-history
SHSE:688203 Earnings and Revenue History April 1st 2024
SHSE: 688203 2024 年 4 月 1 日的收益和收入歷史記錄

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

To properly understand Zhejiang Hisun BiomaterialsLtd's profit results, we need to consider the CN¥2.8m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. If Zhejiang Hisun BiomaterialsLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

爲了正確了解浙江海正生物材料有限公司的利潤業績,我們需要考慮不尋常項目帶來的280萬元人民幣的收益。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。我們統計了全球大多數上市公司的數字,不尋常的物品在自然界中很常見。這正如你所預料的那樣,因爲這些增強被描述爲 “不尋常”。如果浙江海正生物材料有限公司認爲這一貢獻不會重演,那麼在其他條件相同的情況下,我們預計其本年度的利潤將下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Zhejiang Hisun BiomaterialsLtd.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對浙江海正生物材料有限公司的資產負債表分析

Our Take On Zhejiang Hisun BiomaterialsLtd's Profit Performance

我們對浙江海正生物材料有限公司盈利表現的看法

We'd posit that Zhejiang Hisun BiomaterialsLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Zhejiang Hisun BiomaterialsLtd's true underlying earnings power is actually less than its statutory profit. Sadly, its EPS was down over the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Every company has risks, and we've spotted 1 warning sign for Zhejiang Hisun BiomaterialsLtd you should know about.

我們認爲,浙江海正生物材料有限公司的法定收益並不能完全反映持續的生產力,因爲這筆巨額不尋常。因此,在我們看來,浙江海正生物材料有限公司的真正基礎盈利能力實際上可能低於其法定利潤。不幸的是,在過去的十二個月中,其每股收益有所下降。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。因此,如果你想更深入地研究這隻股票,那麼考慮它面臨的任何風險至關重要。每家公司都有風險,我們發現了一個你應該知道的浙江海正生物材料有限公司的警告信號。

Today we've zoomed in on a single data point to better understand the nature of Zhejiang Hisun BiomaterialsLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單一數據點,以更好地了解浙江海正生物材料有限公司利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論